Insmed Inc (INSM)vsJasper Therapeutics Inc (JSPR)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
JSPR
Jasper Therapeutics Inc
$1.09
-5.22%
HEALTHCARE · Cap: $34.42M
Smart Verdict
WallStSmart Research — data-driven comparison
JSPR leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
JSPR
Avoid27
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Reasonable price relative to book value
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : JSPR
The strongest argument for JSPR centers on Price/Book.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : JSPR
The primary concerns for JSPR are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while JSPR is a value play — different risk/reward profiles.
JSPR carries more volatility with a beta of 3.12 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
JSPR generates stronger free cash flow (-17M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 27/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Jasper Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Jasper Therapeutics Inc (JSPR) is an innovative biopharmaceutical firm at the forefront of hematopoietic stem cell therapy, aimed at enhancing patient outcomes for severe diseases such as sickle cell disease and targeted blood cancers. The company's pioneering approach leverages advanced technologies to minimize transplant-related risks and address critical needs in the hematology market. With a robust intellectual property portfolio and strategic partnerships, Jasper is positioned to drive its clinical pipeline forward, underscoring its commitment to transformative advancements in regenerative medicine.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?